Cellectis gets access to a Japanese firm's iPS cell patents

10/18/2010 | Google

France's Cellectis has secured iPS Academia Japan's patents for induced pluripotent stem cells, according to a report by Kyodo News. The agreement allows Cellectis to use the cells to create treatments and to test the efficacy of drug candidates.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA